265 related articles for article (PubMed ID: 19169493)
1. Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.
Della Manna T; Battistim C; Radonsky V; Savoldelli RD; Damiani D; Kok F; Pearson ER; Ellard S; Hattersley AT; Reis AF
Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1350-5. PubMed ID: 19169493
[TBL] [Abstract][Full Text] [Related]
2. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
Shimomura K; Hörster F; de Wet H; Flanagan SE; Ellard S; Hattersley AT; Wolf NI; Ashcroft F; Ebinger F
Neurology; 2007 Sep; 69(13):1342-9. PubMed ID: 17652641
[TBL] [Abstract][Full Text] [Related]
3. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas.
Dupont J; Pereira C; Medeira A; Duarte R; Ellard S; Sampaio L
J Pediatr Endocrinol Metab; 2012; 25(3-4):367-70. PubMed ID: 22768671
[TBL] [Abstract][Full Text] [Related]
4. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
Slingerland AS; Nuboer R; Hadders-Algra M; Hattersley AT; Bruining GJ
Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
[TBL] [Abstract][Full Text] [Related]
5. AV59M KCNJ11 gene mutation leading to intermediate DEND syndrome in a Chinese child.
Sang Y; Ni G; Gu Y; Liu M
J Pediatr Endocrinol Metab; 2011; 24(9-10):763-6. PubMed ID: 22145471
[TBL] [Abstract][Full Text] [Related]
6. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.
Zung A; Glaser B; Nimri R; Zadik Z
J Clin Endocrinol Metab; 2004 Nov; 89(11):5504-7. PubMed ID: 15531505
[TBL] [Abstract][Full Text] [Related]
7. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
Lau E; Correia C; Freitas P; Nogueira C; Costa M; Saavedra A; Costa C; Carvalho D; Fontoura M
Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
[TBL] [Abstract][Full Text] [Related]
8. First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment.
Ioacara S; Flanagan S; Fröhlich-Reiterer E; Goland R; Fica S
J Diabetes Investig; 2017 Sep; 8(5):716-719. PubMed ID: 28083968
[TBL] [Abstract][Full Text] [Related]
9. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
Mlynarski W; Tarasov AI; Gach A; Girard CA; Pietrzak I; Zubcevic L; Kusmierek J; Klupa T; Malecki MT; Ashcroft FM
Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
[TBL] [Abstract][Full Text] [Related]
10. Molecular and clinical features of K
Hashimoto Y; Dateki S; Hirose M; Satomura K; Sawada H; Mizuno H; Sugihara S; Maruyama K; Urakami T; Sugawara H; Shirai K; Yorifuji T
Pediatr Diabetes; 2017 Nov; 18(7):532-539. PubMed ID: 27681997
[TBL] [Abstract][Full Text] [Related]
11. Permanent neonatal diabetes mellitus caused by a novel mutation in the KCNJ11 gene.
Doneray H; Houghton J; Tekgunduz KS; Balkir F; Caner I
J Pediatr Endocrinol Metab; 2014 Mar; 27(3-4):367-71. PubMed ID: 24150202
[TBL] [Abstract][Full Text] [Related]
12. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
Al-Mahdi M; Al Mutair A; Al Balwi M; Hussain K
Ann Saudi Med; 2010; 30(2):162-4. PubMed ID: 20220270
[TBL] [Abstract][Full Text] [Related]
13. DEND syndrome due to V59A mutation in KCNJ11 gene: unresponsive to sulfonylureas.
Itoh S; Matsuoka H; Yasuda Y; Miyake N; Suzuki K; Yorifuji T; Sugihara S
J Pediatr Endocrinol Metab; 2013; 26(1-2):143-6. PubMed ID: 23382304
[TBL] [Abstract][Full Text] [Related]
14. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.
Mohamadi A; Clark LM; Lipkin PH; Mahone EM; Wodka EL; Plotnick LP
Pediatr Diabetes; 2010 May; 11(3):203-7. PubMed ID: 19686306
[TBL] [Abstract][Full Text] [Related]
15. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
Mancioppi V; Pozzi E; Zanetta S; Missineo A; Savastio S; Barbetti F; Mellone S; Giordano M; Rabbone I
Front Endocrinol (Lausanne); 2023; 14():1143736. PubMed ID: 37251668
[TBL] [Abstract][Full Text] [Related]
16. Sulphonylurea treatment does not improve psychomotor development in children with KCNJ11 mutations causing permanent neonatal diabetes mellitus accompanied by developmental delay and epilepsy (DEND syndrome).
Sumnik Z; Kolouskova S; Wales JK; Komarek V; Cinek O
Diabet Med; 2007 Oct; 24(10):1176-8. PubMed ID: 17888143
[No Abstract] [Full Text] [Related]
17. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
Babiker T; Vedovato N; Patel K; Thomas N; Finn R; Männikkö R; Chakera AJ; Flanagan SE; Shepherd MH; Ellard S; Ashcroft FM; Hattersley AT
Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
[TBL] [Abstract][Full Text] [Related]
18. Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with the KCNJ11/S225T, del226-232 mutation.
Battaglia D; Lin YW; Brogna C; Crinò A; Grasso V; Mozzi AF; Russo L; Spera S; Colombo C; Ricci S; Nichols CG; Mercuri E; Barbetti F
Pediatr Diabetes; 2012 Dec; 13(8):656-60. PubMed ID: 22694282
[TBL] [Abstract][Full Text] [Related]
19. KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features.
Gloyn AL; Diatloff-Zito C; Edghill EL; Bellanné-Chantelot C; Nivot S; Coutant R; Ellard S; Hattersley AT; Robert JJ
Eur J Hum Genet; 2006 Jul; 14(7):824-30. PubMed ID: 16670688
[TBL] [Abstract][Full Text] [Related]
20. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
Bremer AA; Ranadive S; Lustig RH
Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
